President Donald J. Trump has nominated Alex Azar II, the head of pharmaceutical company Eli Lilly’s U.S.-based operations until this past January, to be his next HHS secretary, as reported by The New York Times.
Reports indicate that if confirmed, Azar would play a critical role in implementing the president’s efforts to crack down on drug prices in the U.S and the administration’s initiatives to repeal and replace the Affordable Care Act.
At least one Democrat was quick to criticize the nomination.
“President Trump has railed against the pharmaceutical industry ‘getting
Uncategorized